Stock AURA AURA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Aura Biosciences, Inc.

Equities

AURA

US05153U1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
7.35 USD +0.27% Intraday chart for Aura Biosciences, Inc. +4.55% -17.04%
May. 29 Transcript : Aura Biosciences, Inc. - Special Call
May. 09 Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Aura Biosciences Shares Rise Following Q4 Results
MT
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
CI
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Aura Biosciences, Inc. Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-Sar) in Early-Stage Choroidal Melanoma
CI
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
CI
Aura Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
AURA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Aura Biosciences, Inc. Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration At the Macula Society 46Th Annual Meeting
CI
AURA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Aura Announces Inc. Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
CI
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Au-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented At Aao 2022
CI
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
CI
Aura Biosciences Inc. to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
CI
AURA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Aura Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Aura Biosciences Receives Fda Fast Track Designation for Belzupacap Sarotalocan (Au-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AURA Stock
  4. News Aura Biosciences, Inc.
  5. Highlights